CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Bloom, A Joseph ^a   Martinez, Maribel ^a   Chen, Li Shiun ^a   Bierut, Laura J ^a   Murphy, Sharon E ^b   Goate, Alison ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYTOCHROME P450 2B6; MESSENGER RNA; NICOTINE;

ALLELE; ARTICLE; CYP2B6 GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; METABOLISM; RNA SPLICING; SMOKING CESSATION;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; COTININE; GENOTYPE; HAPLOTYPES; HUMANS; NICOTINE; POLYMORPHISM, GENETIC; RNA SPLICING; SMOKING CESSATION;

EID: 84896697913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079700     Document Type: Article

References (58)

1. Sullivan PF, Kendler KS (1999) The genetic epidemiology of smoking. Nicotine Tob Res 1 Suppl 2: S51 257; discussion S69270.
2. Li MD (2003) The genetics of smoking related behavior: a brief review. Am J Med Sci 326: 1682173.
3. Koopmans JR, Slutske WS, Heath AC, Neale MC, Boomsma DI (1999) The genetics of smoking initiation and quantity smoked in Dutch adolescent and young adult twins. Behav Genet 29: 3832393.
4. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, et al. (2010) Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 42: 4482453.
5. (2010) Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet 42: 4412447.
6. Bloom AJ, Harari O, Martinez M, Madden PA, Martin NG, et al. (2012) Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6. Hum Mol Genet 21: 305023062.
7. Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB (2010) Rare variants create synthetic genome-wide associations. PLoS Biol 8: e1000294.
8. Al Koudsi N, Tyndale RF (2010) Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. Xenobiotica 40: 3812392.
9. Dicke KE, Skrlin SM, Murphy SE (2005) Nicotine and 4-(methylnitrosamino)- 1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos 33: 176021764.
10. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, et al. (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28: 122221230.
11. King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, et al. (2012) Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology 37: 6412650.
12. Malaiyandi V, Sellers EM, Tyndale RF (2005) Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 77: 1452158.
13. Liu T, David SP, Tyndale RF, Wang H, Zhou Q, et al. (2011) Associations of CYP2A6 genotype with smoking behaviors in southern China. Addiction 106: 9852994.
14. Keren H, Lev-Maor G, Ast G (2010) Alternative splicing and evolution: diversification, exon definition and function. Nat Rev Genet 11: 3452355.
15. Mukherjee O, Wang J, Gitcho M, Chakraverty S, Taylor-Reinwald L, et al. (2008) Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. Hum Mutat 29: 5122521.
16. Wang GS, Cooper TA (2007) Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 8: 7492761.
17. Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3: 2852298.
18. McVety S, Li L, Gordon PH, Chong G, Foulkes WD (2006) Disruption of an exon splicing enhancer in exon 3 of MLH1 is the cause of HNPCC in a Quebec family. J Med Genet 43: 1532156.
19. Suphapeetiporn K, Kongkam P, Tantivatana J, Sinthuwiwat T, Tongkobpetch S, et al. (2006) PTEN c.511C.T nonsense mutation in a BRRS family disrupts a potential exonic splicing enhancer and causes exon skipping. Jpn J Clin Oncol 36: 8142821.
20. Nielsen KB, Sorensen S, Cartegni L, Corydon TJ, Doktor TK, et al. (2007) Seemingly neutral polymorphic variants may confer immunity to splicinginactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer. Am J Hum Genet 80: 4162432.
21. Kashima T, Rao N, David CJ, Manley JL (2007) hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. Hum Mol Genet 16: 314923159.
22. Gaildrat P, Krieger S, Di Giacomo D, Abdat J, Revillion F, et al. (2012) Multiple sequence variants of BRCA2 exon 7 alter splicing regulation. J Med Genet.
23. Burgess R, MacLaren RE, Davidson AE, Urquhart JE, Holder GE, et al. (2009) ADVIRC is caused by distinct mutations in BEST1 that alter pre-mRNA splicing. J Med Genet 46: 6202625.
24. Bloom AJ, Harari O, Martinez M, Zhang X, McDonald SA, et al. (2013) A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele. Pharmacogenet Genomics.
25. Fairbrother WG, Holste D, Burge CB, Sharp PA (2004) Single nucleotide polymorphism-based validation of exonic splicing enhancers. PLoS Biol 2: E268.
26. Carlini DB, Genut JE (2006) Synonymous SNPs provide evidence for selective constraint on human exonic splicing enhancers. J Mol Evol 62: 89298.
27. Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, et al. (2008) Aberrant splicing caused by single nucleotide polymorphism c.516G.T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 325: 2842292.
28. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, et al. (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307: 9062922.
29. Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, et al. (2007) Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet 16: 24235.
30. Bloom J, Hinrichs AL, Wang JC, von Weymarn LB, Kharasch ED, et al. (2011) The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. Pharmacogenet Genomics 21: 4032416.
31. Stephens M, Donnelly P (2003) A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73: 116221169.
32. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68: 9782989.
33. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 2632265.
34. Ring HZ, Valdes AM, Nishita DM, Prasad S, Jacob P, 3rd, et al. (2007) Genegene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. Pharmacogenet Genomics 17: 100721015.
35. Lang T, Klein K, Richter T, Zibat A, Kerb R, et al. (2004) Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 311: 34243.
36. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, et al. (2008) SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 24: 293822939.
37. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, et al. (2004) Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14: 2252238.
38. Miles JS, McLaren AW, Wolf CR (1989) Alternative splicing in the human cytochrome P450IIB6 gene generates a high level of aberrant messages. Nucleic Acids Res 17: 824128255.
39. Heil SG, van der Ende ME, Schenk PW, van der Heiden I, Lindemans J, et al. (2012) Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals. Ther Drug Monit 34: 1532159.
40. Maimbo M, Kiyotani K, Mushiroda T, Masimirembwa C, Nakamura Y (2012) CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. Eur J Clin Pharmacol 68: 2672271.
41. Sanchez A, Cabrera S, Santos D, Valverde MP, Fuertes A, et al. (2011) Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients. Antimicrob Agents Chemother 55: 531425324.
42. Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, et al. (2011) High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J.
43. Mukonzo JK, Roshammar D, Waako P, Andersson M, Fukasawa T, et al. (2009) A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 68: 6902699.
44. Levran O, Peles E, Hamon S, Randesi M, Adelson M, et al. (2011) CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol.
45. Bunten H, Liang WJ, Pounder D, Seneviratne C, Osselton MD (2011) CYP2B6 and OPRM1 gene variations predict methadone-related deaths. Addict Biol 16: 1422144.
46. Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, et al. (2006) ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80: 6682681.
47. Torimoto Y, Kohgo Y (2008) [Cyclophosphamide and CYP2B6]. Gan To Kagaku Ryoho 35: 109021093.
48. Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, et al. (2007) Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics 17: 4312445.
49. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, et al. (2003) Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 3: 53261.
50. Honda M, Muroi Y, Tamaki Y, Saigusa D, Suzuki N, et al. (2011) Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether. Drug Metab Dispos 39: 186021865.
51. Crane AL, Klein K, Zanger UM, Olson JR (2012) Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism. Toxicology 293: 1152122.
52. Ariyoshi N, Ohara M, Kaneko M, Afuso S, Kumamoto T, et al. (2011) Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262. Drug Metab Dispos 39: 204522048.
53. Qin WJ, Zhang W, Liu ZQ, Chen XP, Tan ZR, et al. (2012) Rapid Clinical Induction of Bupropion Hydroxylation by Metamizole in Healthy Chinese Men. Br J Clin Pharmacol.
54. Fan L, Wang JC, Jiang F, Tan ZR, Chen Y, et al. (2009) Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol 65: 4032409.
55. Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, et al. (2002) Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12: 6272634.
56. Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, et al. (2007) CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 62: 6352641.
57. Lee AM, Jepson C, Shields PG, Benowitz N, Lerman C, et al. (2007) CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 16: 131221314.
58. David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, et al. (2007) Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res 9: 8212833.